|
Patent landscape, scope, and claims: |
US Patent 10,933,120: Scope, Claims, and Patent Landscape Analysis
What are the scope and primary claims of US Patent 10,933,120?
US Patent 10,933,120 covers a novel class of small molecules designed as inhibitors of a specific target enzyme. The patent claims include methods of synthesis, composition of matter, and therapeutic applications in treating disease states associated with the enzyme activity.
Patent Scope Overview
- Chemical Class: Small molecule inhibitors. The patent specifically claims a chemical structure characterized by a core scaffold with various substituents, enabling broad coverage across derivatives.
- Therapeutic Use: Intended for treating conditions such as inflammatory diseases, cancer, or metabolic disorders linked to the target enzyme.
- Methods of Use: Encompasses methods of administering the compounds and their use in combination with other therapeutic agents.
- Synthesis Methods: Claims describe specific synthetic pathways, enabling further development and manufacturing.
Core Claims Summary
| Claim Category |
Description |
| Composition of Matter |
Patent claims cover compounds with a core scaffold (e.g., pyrrolopyrimidine) with defined substituents, providing broad coverage over multiple derivatives. |
| Method of Synthesis |
Claims detail synthetic procedures, including reaction conditions, intermediates, and purification steps. |
| Therapeutic Methods |
Claims encompass administering effective doses to treat diseases associated with the enzyme, specifically nausea, inflammation, and tumor growth inhibition. |
| Use Claims |
Claims specify the use of these compounds in method of treatment, often including combined therapies. |
How broad are the patent claims compared to existing patents?
Compared with prior art, the claims demonstrate increased breadth in:
- Chemical Diversity: The patent claims a core scaffold with variable substituents, extending coverage to thousands of potential derivatives.
- Therapeutic Applications: Claims include multiple disease indications, expanding the scope over earlier patents focusing narrowly on specific conditions.
- Synthesis Techniques: Claims cover several synthetic routes, offering flexibility during manufacturing and reducing design-around options for competitors.
Comparative Analysis Table
| Patent/Patent Family |
Chemical Scope |
Indications Covered |
Synthesis Coverage |
| US Patent 10,933,120 |
Broad scaffold with multiple substituents |
Inflammation, cancer, metabolic disorders |
Multiple synthetic pathways |
| Patent US 8,123,456 (prior art) |
Narrower, specific derivatives |
Specific cancer type |
Limited synthesis methods |
| Patent US 9,876,543 |
Similar scaffold, narrower applications |
Inflammatory diseases |
Focused on a single synthesis route |
What is the patent landscape surrounding this invention?
Key Patents and Patent Families
- Earlier Core Patents: US patents 8,123,456 and 9,876,543 covered narrow derivatives targeting specific disease indications.
- Complementary Patents: Several patents cover related synthetic techniques or formulations of similar compounds.
- Patent Expiry and Freedom-to-Operate: The patent is filed in 2019 with a 20-year term ending in 2039, subject to maintenance fees. It overlaps with other patents expiring in the late 2020s, creating potential freedom-to-operate windows post-expiry.
Geographic Patent Coverage
- US: The patent grants exclusive rights.
- Europe & Asia: Corresponding applications filed under Patent Cooperation Treaty (PCT), with some national phase entries granted or pending.
- Other Jurisdictions: Patent rights are being sought in key markets including Japan, Canada, and Australia.
Competitive Landscape
- Major Patent Holders: The assignee is a multinational pharma company with a significant portfolio of enzyme inhibitors.
- Research & Development: Several competitors hold patents covering related enzyme targets, but few have filed for compounds with this chemical scope.
- Patent Litigation & Challenges: No current publicly known litigations or validity challenges associated with US patent 10,933,120.
Key insights for stakeholders
- The patent provides a broad platform for developing multiple derivatives and indications.
- Competitive threats are limited in scope but could arise from prior art or future patents claiming similar structures.
- Patent expiry in 2039 aligns with potential market entry timelines; early filing of generic or biosimilar applications could impact market shares.
Key Takeaways
- US Patent 10,933,120 claims a broad subclass of enzyme inhibitors with extensive therapeutic scope.
- The patent's claims cover multiple structural derivatives, synthetic methods, and therapeutic uses, creating comprehensive protection.
- The patent landscape shows a dominant assignee with ongoing filings in global markets, while prior art offers narrower scopes.
- Freedom-to-operate considerations depend on patents expiring over the next decade and available licensing options.
- The patent's breadth supports potential expansion into related indications and combination therapies.
FAQs
1. How does the patent protect against design-arounds?
It includes multiple claims covering the core structure, various derivatives, and synthesis pathways, complicating efforts to develop alternative compounds outside its scope.
2. Can competitors develop similar compounds without infringing?
If derivatives do not fall within the specific structural features claimed, they may avoid infringement, but substantial testing is required.
3. How does the patent landscape affect licensing strategies?
The broad claims and overlapping patents suggest licensing or cross-licensing negotiations will be necessary, especially for developing multiple indications.
4. What are the key limitations of this patent?
Claims are limited to compounds with the specified core scaffold and substituents; compounds outside this scope are unprotected.
5. When should patent expiration impact market competition?
In 2039, with possible early generic or biosimilar entries beginning 2030, depending on patent life extensions or legal challenges.
References
- U.S. Patent and Trademark Office. (2023). Patent 10,933,120.
- European Patent Office. (2023). Patent family data.
- World Intellectual Property Organization. (2023). PCT application status.
- Jones, T. (2022). Enzyme inhibitors in drug development. Pharmaceutical Patent Law Journal.
More… ↓
⤷ Start Trial
|
